77 related articles for article (PubMed ID: 30268172)
1. Neoadjuvant
Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
[TBL] [Abstract][Full Text] [Related]
2. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.
de Geus SWL; Kasumova GG; Eskander MF; Ng SC; Kent TS; James Moser A; Vahrmeijer AL; Callery MP; Tseng JF
J Gastrointest Surg; 2018 Feb; 22(2):214-225. PubMed ID: 29235000
[TBL] [Abstract][Full Text] [Related]
3. Trends in the treatment of resectable pancreatic adenocarcinoma.
Raigani S; Ammori J; Kim J; Hardacre JM
J Gastrointest Surg; 2014 Jan; 18(1):113-23. PubMed ID: 24002769
[TBL] [Abstract][Full Text] [Related]
4. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study.
Han D; Gao F; Liu JL; Wang H; Fu Q; Yang GW
BMC Cancer; 2021 May; 21(1):560. PubMed ID: 34001035
[TBL] [Abstract][Full Text] [Related]
5. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.
Kang CM; Chung YE; Park JY; Sung JS; Hwang HK; Choi HJ; Kim H; Song SY; Lee WJ
J Gastrointest Surg; 2012 Mar; 16(3):509-17. PubMed ID: 22183861
[TBL] [Abstract][Full Text] [Related]
6. Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China.
Chen Y; Hao J; Ma W; Tang Y; Gao C; Hao X
J Gastrointest Surg; 2011 Jun; 15(6):1026-34. PubMed ID: 21484493
[TBL] [Abstract][Full Text] [Related]
7. Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals.
Dhar VK; Hoehn RS; Kim Y; Xia BT; Jung AD; Hanseman DJ; Ahmad SA; Shah SA
J Gastrointest Surg; 2018 Jan; 22(1):98-106. PubMed ID: 28849353
[TBL] [Abstract][Full Text] [Related]
8. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.
Dimou F; Sineshaw H; Parmar AD; Tamirisa NP; Jemal A; Riall TS
J Gastrointest Surg; 2016 Jan; 20(1):93-103; discussion 103. PubMed ID: 26503262
[TBL] [Abstract][Full Text] [Related]
9. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?
Cooper AB; Parmar AD; Riall TS; Hall BL; Katz MH; Aloia TA; Pitt HA
J Gastrointest Surg; 2015 Jan; 19(1):80-6; discussion 86-7. PubMed ID: 25091851
[TBL] [Abstract][Full Text] [Related]
10. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?
Barnes CA; Krepline AN; Aldakkak M; Clarke CN; Christians KK; Khan AH; Hunt BC; Ritch PS; George B; Hall WA; Erickson BA; Evans DB; Tsai S
J Gastrointest Surg; 2017 Nov; 21(11):1793-1803. PubMed ID: 28849366
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis.
Shaib WL; Zakka K; Huang W; Chen Z; Alese OB; Wu C; Akce M; El-Rayes BF
Pancreas; 2021 Apr; 50(4):529-536. PubMed ID: 33939665
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrospective multi-institutional analysis.
Shimizu T; Maeda S; Link J; Deranteriassian A; Premji A; Verma A; Chervu N; Park J; Girgis M; Benharash P; Hines J; Wainberg Z; Wolfgang C; Burns W; Yu J; Fernandez-Del Castillo C; Lillemoe K; Ferrone C; Donahue T
Surgery; 2024 May; 175(5):1377-1385. PubMed ID: 38365548
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer.
Laurence JM; Tran PD; Morarji K; Eslick GD; Lam VW; Sandroussi C
J Gastrointest Surg; 2011 Nov; 15(11):2059-69. PubMed ID: 21913045
[TBL] [Abstract][Full Text] [Related]
14. Analyzing the Impact of Compliance with National Guidelines for Pancreatic Cancer Care Using the National Cancer Database.
Jaap K; Fluck M; Hunsinger M; Wild J; Arora T; Shabahang M; Blansfield J
J Gastrointest Surg; 2018 Aug; 22(8):1358-1364. PubMed ID: 29594911
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer.
Gleeson EM; Leigh N; Golas BJ; Magge D; Sarpel U; Hiotis SP; Labow DM; Pintova S; Cohen NA
Pancreas; 2021 Sep; 50(8):1163-1168. PubMed ID: 34714279
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer.
Evans D; Ghassemi N; Hajibandeh S; Hajibandeh S; Romman S; Laing RW; Durkin D; Athwal TS
Surgery; 2024 Jun; 175(6):1470-1479. PubMed ID: 38160086
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival and prognostic indicators in small (Pongprasobchai S; Pannala R; Smyrk TC; Bamlet W; Pitchumoni S; Ougolkov A; de Andrade M; Petersen GM; Chari ST
Pancreatology; 2008; 8(6):587-92. PubMed ID: 18849640
[TBL] [Abstract][Full Text] [Related]
18. Invited commentary for "Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer".
House MG
Surgery; 2024 Jun; 175(6):1480-1481. PubMed ID: 38627104
[No Abstract] [Full Text] [Related]
19. Understanding surgical attrition for "resectable" pancreatic cancer.
Kakish H; Zhao J; Ahmed FA; Elshami M; Hardacre JM; Ammori JB; Winter JM; Ocuin LM; Hoehn RS
HPB (Oxford); 2024 Mar; 26(3):370-378. PubMed ID: 38042732
[TBL] [Abstract][Full Text] [Related]
20. Regarding "Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs".
Su IH; Lund JL; Gaber CE; Sanoff HK; Strassle PD; Duchesneau ED
Oncologist; 2023 Jul; 28(7):e588-e589. PubMed ID: 37210593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
